MedTech Innovator

Nurami Medical Ltd., established in 2014 and based in Haifa, Israel, is a clinical-stage medical device company specializing in the development of innovative solutions for soft tissue repair and regeneration following surgeries. The company's flagship product is a dural substitute patch, designed to replace the damaged dura layer protecting the brain during neurosurgeries. Nurami's technology, based on electrospinning, creates a porous scaffold that enhances tissue regeneration and incorporates a novel temperature-sensitive sealant to prevent infections and cerebrospinal fluid leaks. The company aims to improve patient outcomes and recovery by addressing unmet surgical needs.

Nanochon is focused on creating innovative implantable medical devices designed to address cartilage damage in joints. Utilizing advanced 3D printing techniques and a unique nanomaterial, the company aims to develop solutions that not only replace lost and damaged cartilage but also promote the growth of new tissue. This approach allows medical practitioners to access cost-effective and on-demand devices that enhance treatment outcomes, particularly for young and active patients suffering from knee injuries and diseases. Through its technology, Nanochon seeks to improve the overall quality of care in orthopedics.

Nanobiofab, founded in 2015 and based in Frederick, Maryland, specializes in the development of wearable, smart healthcare and medical devices utilizing nanotechnology for both humans and pets. The company is known for its product, iNose, which enables users to detect, track, and monitor their body's skin vapor-print. This device wirelessly connects to mobile phones to help individuals assess their fat burning rate and evaluate the effectiveness of their exercise routines. Additionally, it provides insights into the effects of dietary choices over time and tracks metabolic rates. Beyond consumer products, Nanobiofab also offers technology and services aimed at accelerating nanomaterial research and development, including nanoprinting solutions and artificial intelligence sensors for telemedicine and personalized healthcare applications.

Nanotis Corporation, founded in 2016 and based in Tokyo, Japan, specializes in the development of instant diagnostic devices, particularly for infectious diseases such as influenza. The company manufactures microchip devices that allow users to achieve rapid and accurate diagnoses, which are essential for medical professionals in practical healthcare settings. By providing timely information, Nanotis aims to enhance the efficiency of healthcare delivery and assist individuals facing health challenges.

Manufacturers of innovative medical devices intended to incorporate sensors, both therapeutic and diagnostic, to help people overcome musculoskeletal problems. The company provides NMES (Neuromuscular Electrical Stimulation) devices that invoke neuroplasticity for optimal outcomes and offers medical devices for physical therapy and rehabilitation, thereby enabling patients to regain and improve their range of motion and function.

Avisi Technologies Inc. is a company based in Philadelphia, Pennsylvania, that focuses on developing innovative solutions for glaucoma treatment. Founded in 2017, the company has created VisiPlate, a next-generation aqueous shunt that utilizes nanotechnology to provide a defense against blindness caused by glaucoma. This advanced technology aims to improve the effectiveness of glaucoma treatments and enhance patient outcomes.

Nanowear, Inc. specializes in the development of textile-based nanosensor technology that facilitates wireless and real-time electrophysiological monitoring. Founded in 2014 and headquartered in Brooklyn, New York, the company offers products such as SimplECG, a remote cardiac monitoring undergarment, and SimpleSense, which focuses on the monitoring and management of congestive heart failure. These garments collect multi-channel electrocardiogram (ECG), heart rate, and respiratory rate data, which is transmitted to a web-based portal accessible by healthcare professionals via a mobile application. Nanowear's technology serves various sectors, including cardiac and neurological health, industrial safety, government, sports medicine, and performance diagnostics, providing accurate and continuous diagnostic data in a cost-effective and unobtrusive manner. The company also maintains a research and development facility in University Park, Pennsylvania.

PixelEXX Systems Inc. is a company specializing in the development of innovative imaging devices aimed at cancer diagnosis. Founded in 2008 and headquartered in Saint Louis, Missouri, the company focuses on creating advanced nanoarrays that capture molecular signals related to cellular activity. Their proprietary technology features novel nano resonant photodiodes that enhance sensitivity and allow the capture of both wavelength and polarization information without the need for additional components like microlenses or filters. This approach enables clients to optimize imaging and sensing capabilities while reducing size, weight, and power consumption.

2C Tech Corporation, a biotechnology company established in 2008 and headquartered in Irvine, California, specializes in developing innovative medical devices for treating ophthalmic diseases. The company leverages its expertise in nanoparticle technologies to create novel therapeutic approaches, with a current focus on developing a proprietary therapy for patients with retinal degenerative conditions, such as Retinitis Pigmentosa, Macular Degeneration, Glaucoma, and Diabetic Retinopathy. Its flagship product, SeeQ, is an intraocularly delivered device that converts light to electrical energy, mimicking the function of a conventional solar cell.

Fibralign Corporation specializes in the development of advanced biomedical devices using its proprietary Nanoweave® scaffolding technology. This innovative approach allows Fibralign to create products that mimic human tissue structure, influencing cell behavior and collagen fiber orientation to support the body's regenerative processes. The company's first product, the BioBridge® Collagen Matrix, is currently undergoing clinical studies to assess its effectiveness in treating and preventing secondary lymphedema. Additionally, Fibralign is focused on research and development for new applications, including treatments for ischemia and novel delivery systems for stem cells and gene therapy.

HeadSense Medical Ltd. is an early-stage company based in Netanya, Israel, focused on developing non-invasive diagnostic devices for brain health. Established in 2011, the company has created a validated and CE Mark approved intracranial pressure (ICP) monitor that is applicable in various medical fields, including neurosurgery, neurology, emergency medicine, and critical care. The device allows healthcare professionals to diagnose and monitor critical clinical parameters without the need for invasive procedures. In addition to its ICP monitor, HeadSense is actively working on expanding its product offerings to include diagnostic tools for cerebral vasospasm, concussion, and the quantification of traumatic brain injury severity, among others. The company operates in both the U.S. and Israel, aiming to enhance patient outcomes through innovative monitoring solutions.